Dr. Jordan goes to DC: Father of tamoxifen joins Lombardi

Publication
Article
Oncology NEWS Today BlogOncology NEWS Today Blog Vol 18 No 5
Volume 18
Issue 5

V. Craig Jordan, OBE, PhD, DSc, will become the scientific director for the cancer center and vice chairman of the department of oncology at Georgetown University Medical Center and the Lombardi Comprehensive Cancer Center.

V. Craig Jordan, OBE, PhD, DSc, will become the scientific director for the cancer center and vice chairman of the department of oncology at Georgetown University Medical Center and the Lombardi Comprehensive Cancer Center.

Dr. Jordan will take up his post at the Washington, DC-based institutions in July. He will also occupy an endowed chair. Dr. Jordan currently serves as vice president and scientific director for the medical sciences at Fox Chase Cancer Center in Philadelphia, where he holds the Alfred G. Knudson Jr., MD, PhD, Chair in Cancer Research. Dr. Jordan is also an adjunct professor of cancer biology at the University of Pennsylvania and a visiting professor of molecular medicine at the University of Leeds in England.

To learn more about Dr. Jordan’s life and career in “Father of tamoxifen a Brit to the core,” May 2008, visit www.cancernetwork.com

Articles in this issue
Dr. Jordan goes to DC: Father of tamoxifen joins Lombardi
PSA Testing: Don't toss the baby out with the bathwater: Readers respond to “Two major studies add fuel to fire of PSA controversy,” April 2009, Cancer Care Practice & Policy, page 8.
Recent Videos
Results showed no “deleterious reactions” with chlorotoxin-directed cellular therapy in a small cohort of patients with recurrent glioblastoma.
Although 1 of 21 patients with liver-dominant NETs died due to RILD in the phase 1 study, no RILD-induced deaths were observed in the phase 2 trial.
A novel CAR T-cell therapy may bind with more avidity, rather than affinity, to glioblastoma cells, said Michael Barish, PhD.
Using chlorotoxin as a targeting element may bind to more glioblastoma cells than other targeting entities, according to Michael Barish, PhD.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
2 experts are featured in this series.
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
Related Content
Biomarker analyses and real-world comparisons to refine patient selection are ongoing in the phase 2 PLUME trial.

Pembrolizumab Regimen May Show Synergy in Melanoma Populations

Sabrina Serani
November 9th 2025
Article

Biomarker analyses and real-world comparisons to refine patient selection are ongoing in the phase 2 PLUME trial.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
November 6th 2025
Podcast

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

Data from a phase 1a/1b trial show that no patients discontinued STK-012 due to treatment-related adverse effects.

Novel IL-2 Therapy Combo Yields Initial Responses in Nonsquamous NSCLC

Russ Conroy
November 8th 2025
Article

Data from a phase 1a/1b trial show that no patients discontinued STK-012 due to treatment-related adverse effects.

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

While more work must be done to minimize toxicity, antibody-drug conjugates have demonstrated benefits for patients with glioblastoma.

Evaluating the Viability of Antibody Drug Conjugates for Glioblastoma

Tim Cortese
November 7th 2025
Article

While more work must be done to minimize toxicity, antibody-drug conjugates have demonstrated benefits for patients with glioblastoma.

The newly approved dasatinib tablets are therapeutically equivalent and approved in the same indications as reference dasatinib.

FDA Approves Abbreviated NDA for Dasatinib Tablets in Leukemia Indications

Tim Cortese
November 7th 2025
Article

The newly approved dasatinib tablets are therapeutically equivalent and approved in the same indications as reference dasatinib.